Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026

Recruitment for the rheumatoid arthritis (RA) sub-study of the SKYWAY basket trial is complete; Week 12 topline data now expected in Q3 2026

Recruitment for the psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of SKYWAY remain on track; Week 16 topline readouts expected in Q4 2026

SKYLINE platform trial in ulcerative colitis (UC) continues to enroll ahead of schedule; Part A readouts to begin in Q2 2026

WALTHAM, Mass., March 16, 2026 -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases, today announced the completion of recruitment for the RA sub-study of the SKYWAY basket trial and acceleration of expected topline readout to Q3 2026.

“Enrollment in the RA sub-study of SKYWAY has exceeded our expectations and reflects both substantial unmet need as well as investigator enthusiasm for the potential of a long-acting anti-TL1A antibody,” said Joshua Friedman, M.D., Ph.D., SVP of Clinical Development and SKYWAY study lead. “We look forward to delivering the first proof-of-concept data for this mechanism in rheumatic disease in the third quarter, with the potential to advance to pivotal trials next year. Together with readouts from the SKYLINE study, we now expect key data from Spyre’s programs in IBD and rheumatic diseases in every subsequent quarter this year.”

About SKYWAY and SPY072

The SKYWAY Phase 2 trial is a randomized and placebo-controlled study evaluating SPY072 in patients with moderately to severely active RA, PsA, or axSpA with inadequate response to conventional or advanced therapies. Topline proof-of-concept data are expected in Q3 (RA) and Q4 (PsA and axSpA).

SPY072 is an extended half-life investigational antibody targeting TL1A, a cytokine central to T-cell-driven inflammation. Designed for superior potency, convenience, and durability, SPY072 may set a new standard in the treatment of rheumatic diseases with its potential for quarterly or twice-yearly subcutaneous maintenance dosing.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, visit Spyre's website.

For Investors:     
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations
[email protected]

For Media:     
Josie Butler, 1AB
[email protected]